
Keywords: prostatic neoplasms; immunotherapy; ADT; androgen deprivation therapy; APC; antigen presenting cell; CRPC; castration resistant prostate cancer; GM-CSF; granulocyte-macrophage colony-stimulating factor; mCRPC; metastatic castration resistant prostate canc